Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Delcath Systems Logo
Delcath Systems Growth Score
42
CB Rank
106332
Heat Score
43
Delcath Systems is an interventional oncology company that focuses on the treatment of metastatic liver cancer.
Founded
obfuscation
PublicPost-IPO Equity New York, New York, United States101-250 www.delcath.com
Biotechnology
Health Care
Oncology
Pharmaceutical
Overview

Delcath Systems
Total Funding
obfuscation
Growth Score
42
Heat Score
43

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score42
-18 pts
in past quarter
Heat Score 43
-10 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Delcath Systems

CB Rank
106332
Delcath Systems is an interventional oncology company that focuses on the treatment of metastatic liver cancer.
Founded
obfuscation
PublicPost-IPO Equity New York, New York, United States101-250 www.delcath.com
Biotechnology
Health Care
Oncology
Pharmaceutical

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation

Key People

Details

Legal Name Delcath Systems, Inc.
Operating Status Active
Stock Symbol  OTCQB:DCTH
Company Type For Profit
About the Company
Delcath Systems is an interventional oncology company that focuses on the treatment of metastatic liver cancer. Its proprietary product Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure.
Phone Number 2124892102
Contact Email info@delcath.com
Predictions & Insights

Growth Insight

See this Growth Insight
Delcath Systems is
Lorem
 to be growing
Top Contributing Factors
Financial Growth

Products & Services

HEPZATO KIT™ (melphalan) for Injection/Hepatic Delivery System (HDS)
A system for delivering high-dose melphalan chemotherapy directly to the liver via percutaneous hepatic perfusion while filtering the blood to reduce systemic exposure.
CHEMOSAT® Hepatic Delivery System for Melphalan Percutaneous Hepatic Perfusion (PHP)
A medical device used in Europe to perform percutaneous hepatic perfusion delivering melphalan chemotherapy directly to the liver with blood filtration to limit systemic toxicity.

Research & Development

Delcath Systems is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
...

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 14
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Delcath Systems Logo
Post-IPO Equity - Delcath Systems
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Delcath Systems Logo
Post-IPO Equity - Delcath Systems
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Delcath Systems Logo
Post-IPO Equity - Delcath Systems
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Delcath Systems Logo
Post-IPO Equity - Delcath Systems
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Delcath Systems Logo
Post-IPO Equity - Delcath Systems
—
obfuscation
— Post-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 14
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Delcath Systems Logo
Post-IPO Equity - Delcath Systems
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Delcath Systems Logo
Post-IPO Equity - Delcath Systems
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Delcath Systems Logo
Post-IPO Equity - Delcath Systems
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Delcath Systems Logo
Post-IPO Equity - Delcath Systems
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Delcath Systems Logo
Post-IPO Equity - Delcath Systems
—
obfuscation
— Post-IPO Equity

Investors

Market Intelligence
People
View Profiles & Contacts
Headcount 101-250 Employee Profiles 11 Board Members and Advisors 1 Contacts 59

Employee Profiles

Board Members and Advisors

News

News and Press

News•May 26, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 26, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 7, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 7, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

3,062
37.37%
 in past month

IT Spend

$5.4MThis year, Delcath Systems is projected to spend $5.4M on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
Course Builders Logo
Course Builders
97
Google Translate Logo
Google Translate
94
Zoom Logo
Zoom
94

Actively Used Products

13Delcath Systems uses 13 technology products and services including HTML5, jQuery, and  GoDaddy Premium DNS, according to G2 Stack.

Active Website Tech Count

28Delcath Systems is actively using 28 technologies for its website, according to BuiltWith. These include IPhone / Mobile Compatible, SSL by Default, and  Viewport Meta.

Total IP

27The intellectual property of Delcath Systems includes 13 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery. Additionally, Delcath Systems has registered 14 trademarks with the most popular class being 'Medical apparatus and instruments', according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Delcath Systems's headquarters? Delcath Systems is located in New York, New York, United States.Who invested in Delcath Systems? Delcath Systems has 7 investors including Biotechnology Value Fund and  Vivo Capital.When was the last funding round for Delcath Systems? Delcath Systems closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are Delcath Systems's competitors? Alternatives and possible competitors to Delcath Systems may include Frensenius Vascular Care, Sirtex Medical, and  Pentec Health.How much funding has Delcath Systems raised to date? Delcath Systems has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(5eb04bf 1)
|